Array Biopharma, Inc. (ARRY) Posts Q2 Loss of $0.06, Sales Top Expectations

Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $21.76 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Raymond James Reiterates Underperform Rating on Lennar (LEN)
• Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold